Classical immunomodulatory therapy in multiple sclerosis
How it acts, how it works

Amélia Mendes¹, Maria José Sá¹,²

ABSTRACT
Interferon beta (IFNβ) and glatiramer acetate (GA) were the first immunomodulators approved to the treatment of relapsing-remitting multiple sclerosis (MS) and clinically isolated syndromes. Despite the enlargement of the therapeutic armamentarium, IFNβ and GA remain the most widely drugs and the therapeutic mainstay of MS. **Objective:** To review the mechanisms of action of IFNβ and GA and main clinical results in MS. **Results:** IFNβ modulates T and B-cell activity and has effects on the blood-brain barrier. The well proved mechanism of GA is an immune deviation by inducing expression of anti-inflammatory cytokines. Some authors favor the neuroprotective role of both molecules. Clinical trials showed a 30% reduction on the annualized relapse rate and of T2 lesions on magnetic resonance. **Conclusion:** Although the precise mechanisms how IFNβ and GA achieve their therapeutics effects remain unclear, these drugs have recognized beneficial effects and possess good safety and tolerability profiles. The large clinical experience in treating MS patients with these drugs along almost two decades deserves to be emphasized, at a time where the appearance of drugs with more selective mechanisms of action, but potentially less safer, pave the way to a better selection of the most appropriate individualized treatment.

Key words: multiple sclerosis, interferon beta, glatiramer acetate, immunomodulatory therapy.

Correspondence
Amélia Mendes
Department of Neurology
Hospital de São João
Alameda Prof. Hernâni Monteiro
4200-319 Porto - Portugal
E-mail: mendes.amelia@gmail.com

Received 21 December 2010
Received in final form 13 January 2011
Accepted 20 January 2011

¹ MD, Department of Neurology, Hospital de São João, Porto, Portugal; ² MD, PhD, Department of Neurology, Hospital de São João, Porto, Portugal; Health Sciences Faculty, University Fernando Pessoa, Porto, Portugal.
Multiple sclerosis (MS), the most frequent primary demyelinating pathology of the central nervous system (CNS), is a chronic and progressive autoimmune disease characterized by inflammation, demyelination and axonal injury. The etiology of MS is ultimately unknown, although there is evidence that complex multifactorial factors are implicated, in which environmental are hypothesized to interact with genetically susceptible individuals.

The clinical hallmarks of MS may be summarized as follows: the disease typically begins in young adults and affects females more than males (1.77:1); most commonly, MS patients alternate relapses with remission phases (relapsing-remitting MS or RRMS); some of them developing later on a secondary progressive course (SPMS), and in fewer cases, the disease progresses ab initio without (progressive MS or PPMS) or with rare superimposed relapses (transitional or progressive relapsing MS-RPMS); the disease is heterogeneous as regards neurological manifestations, evolution and disability; the diagnosis, based in international consensus criteria, depends strictly on clinical features and paraclinical exams, the most important of which is the magnetic resonance imaging (MRI); these criteria turned feasible the identification of patients with a clinically isolated demyelinating event or syndrome (CIS) that are at risk of conversion to a clinically definite disease (CDMS); finally, the progressive course and consequent neurological deficits inflict a significant disabling condition to the patient and a major burden to relatives, caregivers and society.

Although on the grounds of non-curative approaches, since the early nineties several pharmacological treatments with immunomodulatory properties were developed to treat MS and modify its natural history, commonly designated “disease modifying drugs” (DMD), which recognizable represented a major step in the control of the disease.

In this practical review we will focus on the classical immunomodulators specifically approved in MS - interferon beta (IFNβ) and glatiramer acetate (GA) - highlighting their mechanisms of action (how they act) and their main clinical and imaging effects (how they work), based on the results of pivotal and comparative clinical trials. Despite the fast enlargement of the therapeutic armamentarium for MS in the last years, with the approval of drugs with better efficacy yet potential limiting adverse effects, as mitoxantrone and natalizumab (usually indicated in more severe non-IFNβ-responder cases), and the development of oral drugs, exemplified by the recently FDA approved fingolimod, IFNβ and GA remain up to now the worldwide therapeutic mainstay of MS.

**INTERFERON BETA**

Interferons (IFNs) are proteins secreted by cells and are involved in self defense to viral infections, in the regulation of cell growth and in the modulation of immune responses. Human IFNβ is a glycoprotein primarily produced by fibroblasts with 166 amino acids and 22.5 kDa, which is encoded on chromosome 9 without introns. IFNβ was the first therapy to have proved beneficial effects on the natural course of MS and has two molecules: IFNβ-1a and -1b.

IFNβ-1a is obtained by eukaryote cell lines derived from a Chinese hamster ovary and, similarly to native human beta interferon, is glycosilated and has the complete 166 amino acid sequence; yet, the glycosylation pattern is not necessarily equal to the human. IFNβ-1b is a product of a bacterial (E. coli) cell line and is not glycosilated because bacteria do not glycosylate proteins; additionally the cystein residue has been substituted by a serine at position 17, which prevents incorrect disulphide bond formation and minimizes the risk of impaired folding of the molecules and the consequent reduced activity; also, the methionine at position 1 has been deleted, so the final protein has one less amino acid than the natural IFNβ. Glycosylation decreases aggregates formation and immunogenicity, which may give a lower potency of IFNβ-1a, but, on the other side, IFNβ-1b has a tight binding to human serum albumin, which may contribute to about 10% of IFNβ-1a potency.

**How it acts**

IFNβ binds to a high-affinity type-1 IFN transmembrane receptors and induces a cascade of signaling pathways. After binding to the receptor, phosphorylation and activation of two cytoplasmic tyrosine kinases occur. This leads to activation of latent transcription factors in cell cytoplasm that translocate to the nucleus, which recognizes and activated a gene, cell cycle, apoptosis, and inflammation. Additionally, IFNβ interferes with antigen processing and presentation by downregulating expression of major histocompatibility complex (MHC) class II, and reduces the levels of costimulatory molecules.

**EFFECTS ON T CELLS**

**T cell activation** – IFNβ is believed to reduce T cells activation, including myelin reactive T cells, because interferes with antigen processing and presentation by downregulating expression of major histocompatibility complex (MHC) class II, and reduces the levels of costimulatory molecules and other accessory molecules like intercellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and very late activation antigen-4 (VLA-4).

**T cell differentiation and proliferation** – IFNβ inhibits the expansion of T cell clones, acting as an anti-proliferative agent. The exact mechanism for this anti-proliferative effect is unclear. Recently, it was demonstrated that type I IFNs, in which IFNβ is included,
could activate the Mnk/eIF4E kinase pathway that plays important roles in mRNA translation for IFN-stimulated genes and generation of IFN-inducible anti-proliferative responses\(^6\). Previous studies have indicated that Th17 cells have a critical role in the development of the autoimmune response in MS\(^10\). IFNβ-1a could induce an up-regulation of the TLR (toll-like receptors)-7 signaling pathway and inhibit multiple cytokines involved in Th17 cell differentiation. The authors propose that the exogenously administered high-dose IFNβ-1a augments this naturally occurring regulatory mechanism and provides a therapeutic effect in patients with RRMS\(^11\). Furthermore, IFNβ inhibits the expression of FLIP, an anti-apoptotic protein, leading to an increased incidence of T cells death\(^12\) and restores T-regulatory cell activity\(^6\).

**EFFECTS ON CYTOKINES AND CHEMOKINES**

It has been postulated that the modulation of the immune response by IFNβ may involve an immune deviation, consisting in a reduction of the expression of Th1 induced cytokines while enhancing Th2 responses\(^4\). Additionally IFNβ has effects on chemokines: it could mediate activity of the chemokine receptor CCR7 which is important to direct the entry of T lymphocytes to the peripheral lymph nodes rather than to the CNS\(^9\). Another chemokine, Regulated on Activation, Normal T  
Expressed and Secreted (RANTES), appears to play a role in the pathogenesis of RRMS and was observed a decrease of its sera and peripheral blood adherent mononuclear cell levels triggered by IFNβ-1b\(^13\). A recent study suggested that peripheral upregulation of the chemokines by IFNβ may reduce the chemoattraction of immune cells to the CNS\(^14\).

**ANTIGEN PRESENTATION**

Furthermore, IFNβ is postulated to inhibit antigen presentation to T cells in conjunction with MHC and co-stimulatory molecules as CD80 and CD86, which is a crucial event in the ensuing immune response\(^7\). Another mechanism by which IFNβ can affect antigen presentation is by counteracting the effect of IFNγ, because the latter cytokine is a potent promoter of MHC class II expression on many cell types\(^8\).

**EFFECTS ON B CELLS**

IFNβ upregulates a B-cell survival factor (BAAF) and for those patients in whom B cells play a major important role, this would be a quite undesirable consequence of IFNβ therapy. This might partially explain inter-individual differences in the therapeutic response. Otherwise, the systemic induction of BAFF by IFNβ therapy might facilitate the occurrence of various autoantibodies and IFN neutralizing antibodies (NAbs). The authors conclude that individual MS patients with evidence for a significant role of B cells do not appear to be ideal candidates for IFNβ therapy\(^23\). However, B cells may trigger neurotrophic cytokines that exert positive effects on MS autoimmunity, which could outweigh the negative effects of IFNβ-induced BAAF responses\(^6\).

**EFFECTS ON BBB**

IFNβ is able to inhibit the ability of T cells to get into the brain by interfering with the expression of several molecules. It was demonstrated that matrix metalloproteinase type 9 (MMP-9) activity can be decreased by IFNβ-1b treatment in vitro\(^16\), which could difficult the migration of lymphocytes across the fibroconnect of cerebral endothelium. Another study did not find any difference in the MMP-9 levels during the treatment with IFNβ\(^17\). Besides the role of the metalloproteinases, IFNβ can modulate the expression and traffic of other molecules like cytokines, chemokines, adhesion molecules and integrins\(^16\)-\(^18\), improving endothelial barrier function and prevent the transmigration of leukocytes and other neurotoxic mediators across the BBB to sites of CNS inflammation\(^19\). One example is the possible induction of an increase in CD73 expression. Additionally, Uhm and colleagues found that the decrease in cell migration seems to wane with time as patients who have been receiving IFNβ-1b treatment for more than 3.5 years had high levels of T-cell migration that were indistinguishable from those of MS patients who have never been treated with IFNβ\(^19\). IFNβ may interfere with T-cell/endothelial cell adhesion by inhibiting MHC class II expression on endothelial cells, which can also function as ligands for T cells\(^20\) and by decreasing the expression of VLA-4\(^2\). IFNβ also increases serum concentrations of soluble VCAM1 (sVCAM1), which might block leukocyte adhesion to activated cerebral endothelium by binding competitively with the VLA-4 receptor\(^21\). sVCAM1 had been correlated with a reduction in the number of MRI gadolinium-enhancing lesions soon after the initiation of treatment\(^22\).

**ANTIVIRAL EFFECTS**

Both formulations of IFNβ have antiviral properties, although IFNβ-1a seems to be more potent in this field\(^8\). A group of investigators studied the relation of MS-associated retrovirus (MSRV) in MS patients treated with IFNβ. They found that the viral load in the blood was directly related to MS duration and fell below detection limits within 3 months of IFN therapy, suggesting that evaluation of plasmatic MSRV could be considered a prognostic marker for the individual patient to monitor disease progression and therapy outcome\(^22\). Another group aimed to analyze IFNβ antiviral efficiency through the measurement of human herpesvirus-6 (HHV-6)
prevalence in MS patients and they noted a decreased number of reactivations of the virus associated with less relapses (42.8% of patients with viral reactivations experienced at least one relapse versus 22.5% of patients without viral reactivations)⁵⁻⁻³.

**NEUROPROTECTIVE EFFECTS**

Some studies issued potential neuroprotective effects of IFNβ, inducing release of nerve growth factor from astrocytes or stimulate the protection of neurons themselves⁶.

Other investigators tried to measure the axonal injury *in vivo* using MRI spectroscopy to quantify the neuronal marker, N-acetylaspartate (NAA) and its relation with creatine (Cr) and found an increase in NAA/Cr in IFNβ-1b treated MS patients. Their data suggest that the axonal injury could be partially reversible with IFNβ-1b therapy⁷.

**How it works**

**CLINICAL AND MRI OUTCOMES**

The first multicenter, randomized and placebo-controlled study in RRMS patients with IFNβ was published in 1993³. This pivotal study demonstrated that IFNβ-1b 250 µg subcutaneous (SC) produced a 34% reduction in the clinical relapse rate and in the confirmed 1-point EDSS progression rate after 2 years, better than a lower dose (50 µg), yet the latter was not statistically significant compared with the placebo group²⁵. Furthermore, the number and frequency of T2 active lesions on brain MRI were decreased³⁶. Three years later, the results of a phase III trial with a similar design using IFNβ-1a 30 µg/week intramuscular (IM) showed a 37% reduction in the confirmed 1-point EDSS progression rate. The median number of MRI-gadolinium enhancing lesions in MS was 33% inferior comparatively to the placebo arm. This pivotal trial also showed that IFNβ-1a slowed the accumulation of disability²⁷. Since then, several trials confirmed these beneficial effects in RR form of MS²⁸⁻²⁹ and in secondary progressive with relapses³⁰. The patients with CIS who are considered with a high risk of CDMS have a proven benefit from early treatment with IFNβ to decrease clinical and MRI disease activity, as shown by specific studies conducted in CIS, either with IFNβ-1a³⁷ or with IFNβ-1b²⁹.

As regards the route of administration, it does not seem to influence the biological effects of the IFNβ formulations²⁵. Similarly, a dose-dependent effect remains a controversial issue. Although the pivotal trials suggested a dose-response curve, i.e., clinical and MRI outcomes seem to be better with higher doses, the evidence provided by them was considered somewhat equivocal³⁸. However, other studies pointed out a trend to the same result, in which higher dose and more frequently administered IFNβ was favored³⁵⁻³⁶, findings that were not corroborated by others³⁷.

**NEUTRALIZING ANTIBODIES (NABS)**

During treatment with IFNβ, a proportion of MS patients develop NABS. The potential impact of NABS on the efficacy of IFN-β treatment in MS is an area of debate and controversy, although their presence has been associated with a significant hampering of the treatment effect on the relapse rate and both active lesions and burden of disease in MRI. In Europe it is recommended that the patients treated with IFNβ are tested for the presence of NABs at 12 and 24 months of therapy. In patients with NABS, the measurement should be repeated at intervals of 3-6 months and if the titers continue elevated, IFNβ might be discontinued³⁸. The American Academy of Neurology did not find enough evidence to make specific recommendations about when to test, which test to use, how many tests are necessary, and which cutoff titer to apply³⁹.

**Side effects**

Therapy with IFNβ is usually well tolerated. The most frequent side effects are flu-like symptoms and injection-site reaction, which tend to reduce over time. Depression, allergic reaction, haematologic and liver function abnormalities might also be observed⁴⁰. IFNβ is a safe treatment, but usually is not recommended during pregnancy because of the higher risk of fetal loss and low birth weight⁴¹.

**IFN formulations and indications**

The actual commercially available formulations of IFNβ include IFNβ-1a and IFNβ-1b. IFNβ-1a is dosed in 30 µg (Avonex®), 22 or 44 µg (Rebif®). The first is applied once a week by IM and the second three times a week with a SC injection. IFNβ-1b formulations have 250 µg (Betaferon® or Betaseron®, and Extavia®) and are administered by SC injection every other day. All formulations are indicated in RRMS, IFNβ-1a IM and IFNβ-1b are also approved in patients with CIS at risk of conversion to CDMS and IFNβ-1b is furthermore approved in Europe to treat patients with SPMS still with relapses.

**GLATIRAMER ACETATE**

Glatiramer acetate is a synthetic polypeptide composed of four amino acids (L-glutamic acid, L-lysine, L-alanine and L-tyrosine) with an average molecular mass of 4700-11,000 Da. It was discovered in the 1960’s, when studies to develop a polymer resembling myelin basic protein (MBP), a major component of myelin sheath, to the model of autoimmune encephalomyelitis (EAE), were
performed\textsuperscript{45}. One of them, called copolymer 1, demonstrated to decrease or prevent EAE, and was later renamed as GA\textsuperscript{46}.

How it acts

Several mechanisms of action have been proposed, yet the precise biological effects of GA are not fully understood. We present the main effects on T and B lymphocytes and on antigen presenting cells (APCs).

EFFECTS ON T CELLS

Inhibition of myelin reactive T cells and immune deviation – GA binds directly to MHC class II, but also seems to be able to interact with MHC class I\textsuperscript{44}. GA interferes with the activation of myelin-specific T cells based on the observation that it acts as an antagonist to MBP/MHC at MBP-specific T cell receptor (TCR), operating as an altered peptide ligand to the 82-100 epitope of MBP in vitro\textsuperscript{45}, displacing MBP from the binding site on MHC II molecules. Some authors argued that this “TCR antagonism” is controversial and, whether it occurs, is not probably relevant in vivo because GA is unlikely to reach sites where it could compete with MBP. However, GA-reactive Th2 cells are able to cross the BBB and might be activated not only by MBP, but also by other cross-reactive antigens\textsuperscript{44}. Myelin reactive T cells exposed to increasing doses of GA manifest dose-dependent inhibition of proliferation and IFN\gamma production. That proliferative response of T cells to GA decreases with time. In addition, the observed decrease in GA-reactive T cells could be caused by the induction of T cell anergy and clonal elimination\textsuperscript{45}. This mechanism of T cell anergy can occur in the periphery at the injections sites or in their draining lymph nodes where the MBP specific cells might be confronted with GA. The used regimen of daily SC administration may favor the induction of anergy rather than a full immunization that requires longer intervals between doses\textsuperscript{46}. However, some clonal populations of T cells could be expanded, since GA induced the conversion of peripheral CD4+CD25– to CD4+CD25+ regulatory T cells through the activation of transcription factor Foxp3 and lead to proliferation of these cells. However, this fact must be interpreted with caution because almost all activated human T cells express Foxp3\textsuperscript{42}. Therapy with GA may improve the immune regulatory function of CD8+ T cells\textsuperscript{42}. These data suggest that the immunomodulatory effect of GA is attributed to the induction of a cytokine secretion pattern deviation from Th1 to Th2 cytokines, as happens with IFN\beta\textsuperscript{43}, which is the mechanism with the strongest experimental support.

Bystander suppression

Another potential mechanism of action is the so called bystander suppression: a phenomenon of T cells specific to one antigen which suppress the immunological response induced by another antigen\textsuperscript{46}. This implies that GA-reactive Th2 cells are capable of entering the CNS and recognizing cross-reactive antigen(s), probably myelin antigen(s)\textsuperscript{44}. It is characterized by the secretion of anti-inflammatory cytokines by GA-activated T cells after they cross the BBB and accumulate in the CNS\textsuperscript{43}.

EFFECTS ON CELL-PRESENTING ANTIGENS

Although the vast majority of evidence suggests that GA acts primarily at the level of T cells, additional effects on other immune cells cannot be excluded. For example, GA was reported to inhibit a human monocytic cell line, THP-1. In THP-1 cells stimulated with lipopolysaccharide or IFN-\gamma, GA reduced the percentage of cells expressing MHC-DR and DQ antigen and inhibited the production of TNF-\alpha and cathepsin-B. In contrast, the production of interleukin(IL)-1\beta was increased\textsuperscript{47}. This could also indicate antigen-unspecific modes of action. A further study also demonstrated that GA affects monocytes/macrophages by inducing the production of an anti-inflammatory cytokine, the IL-1 receptor antagonist (IL-1Ra), but diminishing the production of IL-1\beta in monocytes, activated by direct contact with stimulated T cells in MS patients and in the EAE model\textsuperscript{48}. IL-1Ra can be transported through the BBB and exert its immunomodulatory effects in both systemic and CNS compartments. In addition to the modulation of the adaptive immune system, GA seems to affect significantly the innate immune system\textsuperscript{49}.

GA may also affect the immune response through modifying APCs into anti-inflammatory type II cells. The process begins with the presentation of GA to CD8+ and CD4+ T cells by APCs. The final step is an alteration of cytokine environment that subsequently affect T-cell differentiation as far as concerned to further cytokine secretion. The T cell CD8+ response becomes oligoclonal with expansion and maintenance of CD8+ clone population over long periods of time, in contrast to what happens to T cells CD4+ which may increase in number\textsuperscript{42}.

NEUROPROTECTIVE EFFECTS

Furthermore, GA specific T cells secrete neurotrophic factors as brain-derived neurotrophic factor and neurotrophic growth factor, which might favor remyelination and axonal protection\textsuperscript{42,43,49}. A study with MRI spectroscopy showed a significant increase in NAA/Cr in a group of treatment naïve patients with RRMS, who received GA compared with untreated patients, suggesting the potential role of GA in axonal metabolic recovery and protection from sublethal injury\textsuperscript{49}. Another potential effect of GA is the delivery of neuroprotective cytokines
to the site of inflammation in patients with MS. So, the role of GA seems to be the creation of an anti-inflammatory and neuroprotective environment instead of suppression the immune activity49.

How it works

CLINICAL AND MRI OUTCOMES

The first studies on MS focusing treatment with copolymer 1 were carried out in late 1970s and early 1980s. Ten years later, a phase III multicentre, double blind and placebo-controlled trial, performed in patients with RRMS, showed that 20 mg GA SC daily was effective in reducing the annualized relapse rate (ARR) by 29% over a 2-year period compared with the placebo51. It also reduced the disability progression in 12%, although this change was not statistically significant51. After 10 years of open label extension of this pivotal trial, patients originally randomized to GA were shown to maintain better outcomes than patients who were originally on placebo55, although the high dropout rate raised some concerns about the power of the study.

As the initial phase III trial did not include MRI endpoints, a European/Canadian study was undertaken to address this specific issue in MS patients treated with GA versus placebo during 9 months51. It was demonstrated a reduction in the frequency and volume of new enhancing lesions, such as a 35% and 8.3% decrease in the number of enhancing lesions and in the median change in T2 burden of disease, respectively, for the treatment arm, an effect that was delayed until 6 months after initiation of treatment51. Later on, in various studies, ARR reductions with use of GA in RRMS patients were found to be much higher than those seen in its pivotal trial51. Recently, the effect of GA on delaying conversion of patients presenting with CIS to CDMS was evaluated in the PreCiSe study, which showed that GA has a beneficial effect for the treatment of patients with this condition54. On the contrary, a large controlled trial with GA in PPMS failed to provide any evidence for benefit in this population55.

Side effects

The results of the studies indicate that GA is generally safe. The most common adverse reaction is a local reaction in the site of injection with erythema and induration. GA is less frequently associated with a transient post-injection systemic reaction of flushing, chest tightness, dyspnea, chest palpitations, and anxiety. This self-limited systemic reaction may be experienced in 15% of the patients and typically resolve within 15-30 minutes without sequelae. No significant laboratory abnormalities have been found. According to the manufacturer, rare cases of non-fatal anaphylaxis have also been reported59. Opportunistic infections, malignancies, and the development of autoimmune diseases are not risks associated with GA52. Although its use is not recommended in pregnancy, there is no evidence to suggest increased risk of adverse fetal or pregnancy outcome59,56.

GA formulation and indications

Glatiramer acetate (Copaxone®) is approved in a SC formulation of 20 mg to be administered once a day, to treat patients with RRMS and with CIS at risk of conversion to CDMS.

Comparative studies

Recently, the results from three head-to-head trials (IFNβ and GA) were published and they did not find significant differences between the two molecules in the primary endpoints evaluating reduction in relapse rates40,57,58. The REGARD study, a randomized, comparative, parallel-group, open-label trial, compared 44 µg of IFNβ-1a SC 3 times a week with 20 mg of GA SC once a day for 96 weeks. There was no significant difference between groups in the time to first relapse and ARR. Regarding MRI outcomes, no significant differences were found in the number and change in volume of T2 active lesions. Patients treated with IFNβ-1a SC had significantly fewer gadolinium enhancing lesions and patients treated with GA experienced significantly less brain atrophy57. BEYOND study compared 3 groups for treatment-naïve early stages RRMS patients: 250 µg of IFNβ-1b, 500 µg IFNβ-1b, both SC dosed every other day and GA 20 mg SC daily over 2 years. No significant differences were found in time to first relapse, overall relapse rates and proportion of patients who remained relapse free during the study period. No differences were found in T1-hypointense lesion volume change among the groups when compared the baseline with the last MRI available or annual time points. Change in total MRI burden and T2 lesion volume was significantly lower in the patients who received GA. However, the differences in T2 lesion volume were noted during the first year but not in years 2 and 3. The overall median change in brain volume was similar in each group. MRI parameters did not differ between patients in either IFNβ-1b doses40. The BECOME study was conducted to determine the efficacy of treatment with IFNβ-1b 250 µg SC every other day versus GA 20 mg SC daily in RRMS or CIS patients, evaluating MRI outcomes (total number of contrast-enhancing lesions plus new non-enhancing lesions on long repetition time scans). The results were similar, as there were no significant differences in the effects of the medications on relapse rates58.

Therefore, IFNβ and GA are both good options to
modify the natural course of MS. The choice between them is usually a challenging issue in MS Clinics, which in our view must be centered on the patient informed decision, after a thorough education about the disease and the real therapeutic expectations. However, the administration routes are rather bothersome to the patients, which could contribute to a reduced therapeutic adherence.

Pivotal studies of IFNβ and GA in MS demonstrated that they are efficacious, lowering the ARR in approximately 30%, the lesion burden and their activity, as well as the brain atrophy as measured by MRI.

Even though the mechanisms of action of these classical immunomodulatory drugs are not completely understood, there is sound evidence that they act on important steps of the inflammatory processes underpinning MS. The appearance of drugs with more specific targets, as monoclonals and orals, increasing therapeutic efficacy, albeit raising new safety and tolerability problems, as well as a better understanding of the immunogenetic profiles of MS patients, are altogether expected to permit a more advanced therapeutic choice in the future. Actually, IFNβ and GA are the better known DMD in MS, with proofs of their safety and tolerability, so the large clinical experience in treating MS patients with them along almost two decades, deserves to be emphasized.

REFERENCES


10. Aramini T, Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allelogen Int 2008;57:115-120.


